




# Oregon

Theodore R. Kulongoski, Governor

**Department of Human Services**  
*Division of Medical Assistance Programs*  
500 Summer Street NE, E35  
Salem, OR 97301-1077  
**Voice (503) 945-5772**  
**FAX (503) 373-7689**  
**TTY (503) 378-6791**

December 29, 2006

To: Pharmacy Providers

From: Allison Knight, Assistant Manager   
DMAP Policy and Planning Section



Subject: PA for Hepatitis C drug therapies

Beginning January 3, 2007, DMAP will require prior authorization (PA) on new prescriptions for Hepatitis C drug therapies: peginterferon, ribavirin and ribavirin with peginterferon. DMAP has notified all of our prescribing providers of this policy change.

The only exception to this policy is for OHP clients who currently receive any of these therapies for Hepatitis C. They may renew their prescriptions without a PA.

These changes result from recommendations by the Drug Utilization Review (DUR) Board and are reflected in DMAP policy revisions for January 2007 (OAR 410-121-0040). The PA policy aligns with the National Institutes of Health *Consensus Development Conference Statement: Management of Hepatitis C 2002* and the Center for Disease Control's optimal treatment standards.

**Questions?** Contact DMAP Provider Services at [dmap.providerservices@state.or.us](mailto:dmap.providerservices@state.or.us) or 1-800-336-6016.

**Have you registered your NPI and taxonomy code(s) with DMAP yet? Access the form online at <http://dhsforms.hr.state.or.us/Forms/Served/OE1038.pdf>.**

OMAP CU Dec 06-324

*“Assisting People to Become Independent, Healthy and Safe”*  
An Equal Opportunity Employer